Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07668518 Phosphoinositide 3-kinase Gamma Peptide Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668518 clinical trial report covering Phosphoinositide 3-kinase Gamma Peptide, Phase 1/2, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07667400 Docetaxel Hypopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667400 clinical trial report covering Docetaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667335 Quemliclustat Ureteral Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667335 clinical trial report covering Quemliclustat, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07670312 XYA-02 Pancreatic adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07670312 clinical trial report covering XYA-02, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07670156 Upadacitinib hemihydrate Job Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07670156 clinical trial report covering Upadacitinib hemihydrate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600127270 Trastuzumab Rezetecan Solid tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
ChiCTR2600127270 clinical trial report covering Trastuzumab Rezetecan, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07673809 GNR-097 Muscular Dystrophy, Duchenne Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07673809 clinical trial report covering GNR-097, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07674667 UNC13A program(Trace Neuroscience) Amyotrophic Lateral Sclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07674667 clinical trial report covering UNC13A program(Trace Neuroscience), Phase 1/2, endpoints, sponsor, geography, readout timing and development whi
Latest Hotspot
8 min read
CTR20262408 Human Cord derived MSC(Tianjin Amcellgene Engineering) Refractory Acute Graft Versus Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262408 clinical trial report covering Human Cord derived MSC(Tianjin Amcellgene Engineering), Phase 1/2, endpoints, sponsor, geography, readout timing
Latest Hotspot
8 min read
NCT07675174 Sitagliptin Phosphate Graft vs Host Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07675174 clinical trial report covering Sitagliptin Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262489 Albumin-Bound Paclitaxel Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262489 clinical trial report covering Albumin-Bound Paclitaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262448 ANS-02 EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262448 clinical trial report covering ANS-02, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.